| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 76 | 2026 | 391 | 9.100 |
Why?
|
| Tuberous Sclerosis | 47 | 2025 | 146 | 7.590 |
Why?
|
| Epilepsy | 44 | 2026 | 872 | 5.990 |
Why?
|
| Neurosurgical Procedures | 29 | 2025 | 326 | 4.800 |
Why?
|
| Drug Resistant Epilepsy | 24 | 2026 | 271 | 4.610 |
Why?
|
| Microglia | 13 | 2025 | 143 | 4.140 |
Why?
|
| Neurosurgery | 9 | 2025 | 71 | 4.080 |
Why?
|
| Brain | 51 | 2026 | 3188 | 2.860 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 16 | 2025 | 48 | 2.680 |
Why?
|
| Brain Neoplasms | 25 | 2024 | 1350 | 2.280 |
Why?
|
| Electroencephalography | 27 | 2026 | 855 | 2.230 |
Why?
|
| Stereotaxic Techniques | 8 | 2026 | 98 | 2.190 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 8 | 2025 | 21 | 2.150 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 12 | 2025 | 45 | 2.080 |
Why?
|
| Vagus Nerve Stimulation | 9 | 2026 | 65 | 2.030 |
Why?
|
| Magnetic Resonance Imaging | 70 | 2026 | 3841 | 1.970 |
Why?
|
| Alzheimer Disease | 12 | 2025 | 877 | 1.940 |
Why?
|
| Interleukin-10 | 5 | 2025 | 186 | 1.910 |
Why?
|
| Seizures | 23 | 2026 | 876 | 1.830 |
Why?
|
| Gray Matter | 8 | 2019 | 50 | 1.810 |
Why?
|
| Antibodies, Monoclonal | 8 | 2025 | 980 | 1.760 |
Why?
|
| T-Lymphocytes, Regulatory | 6 | 2025 | 233 | 1.720 |
Why?
|
| Humans | 279 | 2026 | 130403 | 1.530 |
Why?
|
| Positron-Emission Tomography | 8 | 2025 | 293 | 1.470 |
Why?
|
| Pediatrics | 6 | 2025 | 1244 | 1.460 |
Why?
|
| Epilepsies, Partial | 8 | 2018 | 84 | 1.420 |
Why?
|
| Glial Fibrillary Acidic Protein | 6 | 2025 | 104 | 1.400 |
Why?
|
| Neurosurgeons | 3 | 2025 | 13 | 1.360 |
Why?
|
| CD3 Complex | 2 | 2025 | 93 | 1.350 |
Why?
|
| Child | 103 | 2026 | 26159 | 1.320 |
Why?
|
| Male | 179 | 2026 | 64486 | 1.290 |
Why?
|
| Th17 Cells | 5 | 2026 | 95 | 1.280 |
Why?
|
| Cerebral Cortex | 16 | 2022 | 452 | 1.250 |
Why?
|
| Immunosuppressive Agents | 13 | 2020 | 658 | 1.250 |
Why?
|
| Female | 180 | 2026 | 70343 | 1.210 |
Why?
|
| Treatment Outcome | 63 | 2026 | 12852 | 1.200 |
Why?
|
| Neurofilament Proteins | 7 | 2025 | 36 | 1.190 |
Why?
|
| Child, Preschool | 78 | 2026 | 14982 | 1.180 |
Why?
|
| Hemispherectomy | 6 | 2025 | 29 | 1.170 |
Why?
|
| Laser Therapy | 4 | 2025 | 241 | 1.160 |
Why?
|
| Inflammation | 11 | 2026 | 1481 | 1.080 |
Why?
|
| Astrocytoma | 11 | 2020 | 107 | 1.070 |
Why?
|
| Supratentorial Neoplasms | 2 | 2023 | 41 | 1.070 |
Why?
|
| Adult | 112 | 2026 | 31125 | 1.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 8 | 2025 | 564 | 1.020 |
Why?
|
| Muscle Relaxants, Central | 5 | 2016 | 37 | 0.980 |
Why?
|
| Baclofen | 5 | 2016 | 44 | 0.970 |
Why?
|
| Hydrocephalus | 9 | 2022 | 290 | 0.950 |
Why?
|
| Electrodes, Implanted | 9 | 2025 | 178 | 0.930 |
Why?
|
| Retrospective Studies | 67 | 2025 | 17633 | 0.920 |
Why?
|
| Central Nervous System | 7 | 2025 | 277 | 0.910 |
Why?
|
| Cerebellar Diseases | 3 | 2022 | 78 | 0.900 |
Why?
|
| Phagocytosis | 3 | 2025 | 189 | 0.900 |
Why?
|
| Adolescent | 81 | 2026 | 20731 | 0.880 |
Why?
|
| Gastrointestinal Microbiome | 7 | 2025 | 836 | 0.870 |
Why?
|
| Efficiency | 1 | 2025 | 74 | 0.860 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2016 | 146 | 0.850 |
Why?
|
| Encephalitis | 4 | 2022 | 121 | 0.840 |
Why?
|
| Fatigue | 4 | 2020 | 195 | 0.840 |
Why?
|
| Middle Aged | 85 | 2025 | 28395 | 0.840 |
Why?
|
| Feces | 2 | 2025 | 721 | 0.830 |
Why?
|
| Malformations of Cortical Development | 3 | 2022 | 60 | 0.830 |
Why?
|
| T-Lymphocytes | 14 | 2026 | 1701 | 0.820 |
Why?
|
| Physician Assistants | 1 | 2025 | 81 | 0.820 |
Why?
|
| Mentors | 1 | 2025 | 161 | 0.810 |
Why?
|
| Medulloblastoma | 7 | 2024 | 390 | 0.790 |
Why?
|
| Astrocytes | 5 | 2025 | 284 | 0.790 |
Why?
|
| Interferon Type I | 3 | 2025 | 113 | 0.790 |
Why?
|
| Psychosurgery | 1 | 2023 | 27 | 0.770 |
Why?
|
| Quality of Life | 12 | 2025 | 2070 | 0.760 |
Why?
|
| Muscle Spasticity | 5 | 2016 | 52 | 0.760 |
Why?
|
| Follow-Up Studies | 27 | 2025 | 5204 | 0.740 |
Why?
|
| Cerebellar Neoplasms | 7 | 2024 | 328 | 0.740 |
Why?
|
| Neuroglia | 2 | 2024 | 223 | 0.740 |
Why?
|
| Administration, Intranasal | 4 | 2025 | 129 | 0.730 |
Why?
|
| Disease Progression | 26 | 2025 | 2203 | 0.730 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2022 | 16 | 0.730 |
Why?
|
| Faculty, Medical | 1 | 2025 | 276 | 0.720 |
Why?
|
| Immunologic Factors | 5 | 2021 | 187 | 0.720 |
Why?
|
| Young Adult | 41 | 2026 | 9974 | 0.690 |
Why?
|
| Postoperative Complications | 19 | 2024 | 3105 | 0.690 |
Why?
|
| Interferon-beta | 7 | 2025 | 56 | 0.690 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2025 | 321 | 0.660 |
Why?
|
| Hamartoma | 3 | 2018 | 51 | 0.650 |
Why?
|
| Colitis | 3 | 2018 | 164 | 0.650 |
Why?
|
| Substantia Nigra | 1 | 2020 | 35 | 0.650 |
Why?
|
| Education, Medical, Graduate | 1 | 2025 | 552 | 0.640 |
Why?
|
| Infant | 46 | 2025 | 13276 | 0.630 |
Why?
|
| Gene Expression Profiling | 9 | 2026 | 1828 | 0.610 |
Why?
|
| Animals | 45 | 2026 | 33852 | 0.610 |
Why?
|
| T-Lymphocyte Subsets | 3 | 2021 | 197 | 0.600 |
Why?
|
| Biomarkers | 17 | 2025 | 3395 | 0.600 |
Why?
|
| Adjuvants, Immunologic | 5 | 2019 | 391 | 0.590 |
Why?
|
| Severity of Illness Index | 16 | 2020 | 3030 | 0.580 |
Why?
|
| Neurophysiological Monitoring | 2 | 2018 | 38 | 0.580 |
Why?
|
| Spinal Cord Neoplasms | 4 | 2023 | 68 | 0.570 |
Why?
|
| Cognition Disorders | 5 | 2011 | 556 | 0.560 |
Why?
|
| Atrophy | 14 | 2020 | 244 | 0.560 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2025 | 497 | 0.560 |
Why?
|
| Somatosensory Cortex | 1 | 2018 | 56 | 0.560 |
Why?
|
| Mice, Inbred C57BL | 18 | 2026 | 4698 | 0.560 |
Why?
|
| Infusion Pumps, Implantable | 4 | 2016 | 34 | 0.550 |
Why?
|
| Longitudinal Studies | 23 | 2026 | 1487 | 0.550 |
Why?
|
| Neocortex | 2 | 2018 | 75 | 0.550 |
Why?
|
| Cell Death | 1 | 2018 | 235 | 0.550 |
Why?
|
| Pneumonia | 1 | 2021 | 337 | 0.540 |
Why?
|
| Signal Transduction | 13 | 2026 | 4649 | 0.530 |
Why?
|
| Mice | 28 | 2026 | 18180 | 0.530 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2000 | 150 | 0.530 |
Why?
|
| Fingolimod Hydrochloride | 5 | 2017 | 34 | 0.510 |
Why?
|
| Sjogren-Larsson Syndrome | 1 | 2016 | 2 | 0.510 |
Why?
|
| Meningomyelocele | 3 | 2024 | 275 | 0.500 |
Why?
|
| Muromonab-CD3 | 1 | 2016 | 7 | 0.490 |
Why?
|
| Brain Mapping | 7 | 2024 | 390 | 0.490 |
Why?
|
| MicroRNAs | 6 | 2025 | 896 | 0.480 |
Why?
|
| Peyer's Patches | 1 | 2015 | 17 | 0.480 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2015 | 7 | 0.470 |
Why?
|
| Stem Cell Transplantation | 3 | 2025 | 229 | 0.470 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 30 | 0.470 |
Why?
|
| Cohort Studies | 21 | 2025 | 5084 | 0.470 |
Why?
|
| White Matter | 4 | 2019 | 220 | 0.460 |
Why?
|
| Hypothalamic Diseases | 1 | 2015 | 40 | 0.450 |
Why?
|
| Cytokines | 5 | 2025 | 1331 | 0.450 |
Why?
|
| Craniotomy | 5 | 2016 | 108 | 0.440 |
Why?
|
| Spinal Cord | 6 | 2023 | 261 | 0.440 |
Why?
|
| Adaptation, Psychological | 3 | 2024 | 429 | 0.440 |
Why?
|
| Recovery of Function | 3 | 2025 | 440 | 0.430 |
Why?
|
| Apolipoprotein E4 | 2 | 2025 | 52 | 0.430 |
Why?
|
| Neurons | 5 | 2020 | 2011 | 0.430 |
Why?
|
| Meningeal Neoplasms | 2 | 2014 | 220 | 0.430 |
Why?
|
| Disease Models, Animal | 10 | 2025 | 4654 | 0.420 |
Why?
|
| Radiosurgery | 1 | 2015 | 146 | 0.420 |
Why?
|
| Sturge-Weber Syndrome | 1 | 2014 | 9 | 0.420 |
Why?
|
| Port-Wine Stain | 1 | 2014 | 10 | 0.410 |
Why?
|
| Nervous System Diseases | 2 | 2018 | 397 | 0.410 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2021 | 213 | 0.410 |
Why?
|
| Intestinal Mucosa | 3 | 2026 | 765 | 0.400 |
Why?
|
| Glioma | 6 | 2010 | 523 | 0.400 |
Why?
|
| Mutism | 2 | 2024 | 29 | 0.390 |
Why?
|
| Trans-Activators | 4 | 2005 | 689 | 0.370 |
Why?
|
| Reoperation | 9 | 2019 | 830 | 0.370 |
Why?
|
| Flow Cytometry | 7 | 2018 | 769 | 0.370 |
Why?
|
| Societies, Medical | 3 | 2025 | 791 | 0.360 |
Why?
|
| Electric Stimulation Therapy | 3 | 2026 | 85 | 0.360 |
Why?
|
| Monitoring, Physiologic | 2 | 2012 | 372 | 0.350 |
Why?
|
| Germinoma | 3 | 2010 | 29 | 0.350 |
Why?
|
| Monocytes | 4 | 2026 | 335 | 0.350 |
Why?
|
| Macrophages | 4 | 2019 | 652 | 0.340 |
Why?
|
| Hematoma, Epidural, Cranial | 1 | 2011 | 10 | 0.340 |
Why?
|
| Intracranial Hypotension | 1 | 2011 | 10 | 0.340 |
Why?
|
| Prospective Studies | 16 | 2025 | 6447 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2022 | 3410 | 0.330 |
Why?
|
| Disability Evaluation | 8 | 2025 | 188 | 0.330 |
Why?
|
| Cyclophosphamide | 4 | 2013 | 436 | 0.330 |
Why?
|
| Homeostasis | 4 | 2025 | 715 | 0.330 |
Why?
|
| Aged | 32 | 2025 | 20899 | 0.320 |
Why?
|
| Cervical Vertebrae | 3 | 2024 | 116 | 0.320 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2023 | 258 | 0.310 |
Why?
|
| Autoimmunity | 2 | 2025 | 174 | 0.310 |
Why?
|
| Amyotrophic Lateral Sclerosis | 2 | 2024 | 175 | 0.310 |
Why?
|
| Giant Cell Tumors | 1 | 2009 | 5 | 0.310 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2000 | 222 | 0.300 |
Why?
|
| Frontal Lobe | 2 | 2009 | 111 | 0.300 |
Why?
|
| Neoplasm Recurrence, Local | 7 | 2023 | 1275 | 0.300 |
Why?
|
| Drainage | 1 | 2011 | 248 | 0.300 |
Why?
|
| Connectome | 2 | 2022 | 123 | 0.300 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2014 | 487 | 0.290 |
Why?
|
| Receptors, Immunologic | 3 | 2020 | 124 | 0.290 |
Why?
|
| Transcriptome | 5 | 2026 | 1130 | 0.290 |
Why?
|
| Vagus Nerve | 3 | 2023 | 50 | 0.290 |
Why?
|
| Recurrence | 11 | 2023 | 1475 | 0.280 |
Why?
|
| Neurodegenerative Diseases | 2 | 2025 | 289 | 0.280 |
Why?
|
| Receptors, Growth Factor | 3 | 2000 | 36 | 0.280 |
Why?
|
| Image Processing, Computer-Assisted | 7 | 2017 | 599 | 0.270 |
Why?
|
| Hippocampus | 4 | 2024 | 801 | 0.270 |
Why?
|
| Vancomycin | 3 | 2025 | 221 | 0.270 |
Why?
|
| Mice, Transgenic | 8 | 2025 | 2343 | 0.270 |
Why?
|
| Injections, Spinal | 6 | 2016 | 130 | 0.270 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 2 | 2024 | 10 | 0.270 |
Why?
|
| Meningocele | 2 | 2019 | 18 | 0.270 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2010 | 92 | 0.260 |
Why?
|
| Syringomyelia | 1 | 2007 | 21 | 0.260 |
Why?
|
| Ependymoma | 4 | 2023 | 154 | 0.260 |
Why?
|
| Receptors, Aryl Hydrocarbon | 2 | 2019 | 65 | 0.260 |
Why?
|
| Cerebral Ventricle Neoplasms | 3 | 2015 | 14 | 0.260 |
Why?
|
| Neuroprotective Agents | 1 | 2008 | 162 | 0.260 |
Why?
|
| Autoantibodies | 4 | 2022 | 439 | 0.260 |
Why?
|
| Pilot Projects | 6 | 2021 | 1452 | 0.250 |
Why?
|
| Gene Targeting | 2 | 2017 | 170 | 0.250 |
Why?
|
| Cells, Cultured | 6 | 2021 | 2898 | 0.250 |
Why?
|
| Hemodynamics | 1 | 2011 | 802 | 0.250 |
Why?
|
| Endoscopy | 5 | 2015 | 270 | 0.250 |
Why?
|
| Xeroderma Pigmentosum | 1 | 2026 | 6 | 0.240 |
Why?
|
| Periventricular Nodular Heterotopia | 1 | 2026 | 9 | 0.240 |
Why?
|
| Antigens, CD | 3 | 2019 | 412 | 0.240 |
Why?
|
| Reproducibility of Results | 8 | 2025 | 2923 | 0.240 |
Why?
|
| Neuropsychological Tests | 7 | 2024 | 955 | 0.240 |
Why?
|
| Interferon-gamma | 3 | 2017 | 541 | 0.240 |
Why?
|
| Vein of Galen Malformations | 1 | 2025 | 15 | 0.230 |
Why?
|
| Skull | 3 | 2019 | 153 | 0.230 |
Why?
|
| Mitoxantrone | 2 | 2018 | 27 | 0.230 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2025 | 14 | 0.230 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2025 | 99 | 0.230 |
Why?
|
| Receptors, CXCR3 | 1 | 2025 | 23 | 0.220 |
Why?
|
| Xenon | 1 | 2025 | 11 | 0.220 |
Why?
|
| Oncogene Proteins | 2 | 2002 | 136 | 0.220 |
Why?
|
| Odontoid Process | 1 | 2024 | 11 | 0.220 |
Why?
|
| Immune System | 1 | 2025 | 98 | 0.220 |
Why?
|
| Glatiramer Acetate | 4 | 2019 | 17 | 0.220 |
Why?
|
| Brain Stem | 3 | 1997 | 110 | 0.220 |
Why?
|
| Immunity, Innate | 2 | 2026 | 404 | 0.220 |
Why?
|
| Neuroendoscopy | 2 | 2015 | 31 | 0.220 |
Why?
|
| Mice, Knockout | 5 | 2026 | 3812 | 0.220 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2024 | 22 | 0.220 |
Why?
|
| Chordoma | 1 | 2024 | 18 | 0.220 |
Why?
|
| Efficiency, Organizational | 1 | 2025 | 55 | 0.220 |
Why?
|
| Ataxia | 3 | 2018 | 157 | 0.220 |
Why?
|
| Antineoplastic Agents | 4 | 2018 | 1788 | 0.220 |
Why?
|
| Lymphocytes | 2 | 2026 | 345 | 0.220 |
Why?
|
| Alemtuzumab | 4 | 2018 | 89 | 0.220 |
Why?
|
| Auditory Cortex | 1 | 2024 | 28 | 0.220 |
Why?
|
| Interferon beta-1a | 4 | 2018 | 23 | 0.210 |
Why?
|
| Proteomics | 3 | 2024 | 607 | 0.210 |
Why?
|
| Education, Distance | 1 | 2025 | 69 | 0.210 |
Why?
|
| Speech | 1 | 2024 | 63 | 0.210 |
Why?
|
| Streptococcus anginosus | 1 | 2024 | 10 | 0.210 |
Why?
|
| Neural Stem Cells | 1 | 2025 | 136 | 0.210 |
Why?
|
| Diet, High-Fat | 1 | 2026 | 263 | 0.210 |
Why?
|
| Speech Perception | 1 | 2024 | 56 | 0.210 |
Why?
|
| Gene Expression Regulation | 8 | 2024 | 2343 | 0.210 |
Why?
|
| Tauopathies | 1 | 2025 | 75 | 0.210 |
Why?
|
| Amyloidosis | 1 | 2025 | 69 | 0.210 |
Why?
|
| Lennox Gastaut Syndrome | 1 | 2023 | 8 | 0.210 |
Why?
|
| Immunity | 2 | 2022 | 178 | 0.210 |
Why?
|
| Mastoiditis | 1 | 2024 | 33 | 0.210 |
Why?
|
| Mitochondria | 2 | 2026 | 764 | 0.200 |
Why?
|
| Hysterotomy | 1 | 2024 | 141 | 0.200 |
Why?
|
| Brain Abscess | 1 | 2024 | 54 | 0.200 |
Why?
|
| Laparotomy | 1 | 2024 | 138 | 0.200 |
Why?
|
| Indoles | 1 | 2025 | 199 | 0.200 |
Why?
|
| Acetanilides | 2 | 2020 | 8 | 0.200 |
Why?
|
| Otitis Media | 1 | 2024 | 88 | 0.200 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2025 | 427 | 0.200 |
Why?
|
| Cerebrovascular Trauma | 1 | 2023 | 4 | 0.200 |
Why?
|
| Craniosynostoses | 3 | 2002 | 156 | 0.200 |
Why?
|
| Predictive Value of Tests | 8 | 2025 | 2298 | 0.200 |
Why?
|
| Cognitive Dysfunction | 2 | 2025 | 338 | 0.190 |
Why?
|
| Neurodevelopmental Disorders | 2 | 2020 | 621 | 0.190 |
Why?
|
| Spinal Cord Injuries | 3 | 2020 | 272 | 0.190 |
Why?
|
| Major Histocompatibility Complex | 1 | 2022 | 49 | 0.190 |
Why?
|
| Sinusitis | 1 | 2024 | 119 | 0.190 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2024 | 387 | 0.190 |
Why?
|
| Intracranial Pressure | 2 | 2015 | 218 | 0.190 |
Why?
|
| Minimally Invasive Surgical Procedures | 1 | 2024 | 194 | 0.190 |
Why?
|
| Multiple System Atrophy | 1 | 2022 | 15 | 0.190 |
Why?
|
| Databases, Factual | 5 | 2025 | 1222 | 0.190 |
Why?
|
| DNA Damage | 1 | 2026 | 512 | 0.190 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2025 | 341 | 0.190 |
Why?
|
| DNA Repair | 1 | 2026 | 576 | 0.190 |
Why?
|
| Clone Cells | 3 | 2021 | 152 | 0.190 |
Why?
|
| Age of Onset | 6 | 2021 | 599 | 0.190 |
Why?
|
| Terminology as Topic | 1 | 2024 | 225 | 0.190 |
Why?
|
| Bile Acids and Salts | 1 | 2025 | 259 | 0.190 |
Why?
|
| Multiple Trauma | 1 | 2023 | 62 | 0.190 |
Why?
|
| Burnout, Professional | 1 | 2024 | 133 | 0.180 |
Why?
|
| Genotype | 4 | 2021 | 2607 | 0.180 |
Why?
|
| RNA | 2 | 2018 | 518 | 0.180 |
Why?
|
| Interferon beta-1b | 2 | 2019 | 3 | 0.180 |
Why?
|
| Time Factors | 12 | 2020 | 6183 | 0.180 |
Why?
|
| Neutrophils | 1 | 2024 | 358 | 0.180 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2022 | 8 | 0.180 |
Why?
|
| Putamen | 1 | 2022 | 24 | 0.180 |
Why?
|
| Immunohistochemistry | 6 | 2018 | 1605 | 0.180 |
Why?
|
| Gliosis | 2 | 2015 | 31 | 0.180 |
Why?
|
| Intestines | 1 | 2026 | 588 | 0.180 |
Why?
|
| Mesencephalon | 1 | 2022 | 38 | 0.180 |
Why?
|
| Phenotype | 6 | 2020 | 4475 | 0.180 |
Why?
|
| Lower Urinary Tract Symptoms | 1 | 2022 | 40 | 0.180 |
Why?
|
| Mice, Inbred NOD | 4 | 2016 | 301 | 0.180 |
Why?
|
| Fellowships and Scholarships | 1 | 2025 | 323 | 0.180 |
Why?
|
| Spasms, Infantile | 1 | 2023 | 165 | 0.180 |
Why?
|
| Apolipoproteins E | 2 | 2024 | 187 | 0.180 |
Why?
|
| T Cell Transcription Factor 1 | 2 | 2024 | 7 | 0.180 |
Why?
|
| Streptococcal Infections | 1 | 2024 | 251 | 0.170 |
Why?
|
| Home Infusion Therapy | 1 | 2001 | 6 | 0.170 |
Why?
|
| Oxidative Stress | 1 | 2026 | 798 | 0.170 |
Why?
|
| Natalizumab | 3 | 2016 | 5 | 0.170 |
Why?
|
| B-Lymphocytes | 2 | 2022 | 508 | 0.170 |
Why?
|
| Adrenoleukodystrophy | 1 | 2001 | 12 | 0.170 |
Why?
|
| Receptors, Mitogen | 1 | 2000 | 3 | 0.170 |
Why?
|
| Central Nervous System Diseases | 2 | 2014 | 97 | 0.170 |
Why?
|
| United States | 8 | 2025 | 11826 | 0.170 |
Why?
|
| Sensitivity and Specificity | 6 | 2017 | 2111 | 0.170 |
Why?
|
| Language Development Disorders | 1 | 2022 | 177 | 0.170 |
Why?
|
| Wounds, Nonpenetrating | 1 | 2023 | 214 | 0.170 |
Why?
|
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2020 | 4 | 0.160 |
Why?
|
| Microbiota | 1 | 2026 | 444 | 0.160 |
Why?
|
| Deep Brain Stimulation | 1 | 2026 | 446 | 0.160 |
Why?
|
| Crotonates | 1 | 2020 | 6 | 0.160 |
Why?
|
| Toluidines | 1 | 2020 | 6 | 0.160 |
Why?
|
| Perioperative Period | 1 | 2020 | 51 | 0.160 |
Why?
|
| Peptides | 4 | 2012 | 708 | 0.160 |
Why?
|
| Phosphatidylcholines | 1 | 2020 | 33 | 0.160 |
Why?
|
| Microsurgery | 3 | 2013 | 65 | 0.160 |
Why?
|
| Quantitative Trait Loci | 1 | 2021 | 304 | 0.160 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2022 | 245 | 0.160 |
Why?
|
| Fetoscopy | 1 | 2024 | 480 | 0.160 |
Why?
|
| Microscopy, Confocal | 2 | 2018 | 339 | 0.160 |
Why?
|
| Glioblastoma | 3 | 2019 | 379 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2000 | 201 | 0.160 |
Why?
|
| Adoptive Transfer | 1 | 2021 | 235 | 0.160 |
Why?
|
| Neoplasms, Complex and Mixed | 1 | 1999 | 6 | 0.160 |
Why?
|
| Nerve Fibers, Myelinated | 2 | 2011 | 83 | 0.160 |
Why?
|
| In Vitro Techniques | 4 | 2015 | 809 | 0.160 |
Why?
|
| Lymphoma, B-Cell | 1 | 2021 | 146 | 0.150 |
Why?
|
| Demyelinating Diseases | 3 | 2014 | 69 | 0.150 |
Why?
|
| Infratentorial Neoplasms | 1 | 2020 | 37 | 0.150 |
Why?
|
| Brain Edema | 1 | 2020 | 66 | 0.150 |
Why?
|
| Fluorine Radioisotopes | 1 | 2019 | 11 | 0.150 |
Why?
|
| Dystonia | 1 | 2001 | 169 | 0.150 |
Why?
|
| Organ Specificity | 1 | 2020 | 396 | 0.150 |
Why?
|
| Interleukin-6 | 1 | 2021 | 414 | 0.150 |
Why?
|
| Outpatients | 1 | 2021 | 266 | 0.150 |
Why?
|
| Biomedical Research | 1 | 2025 | 561 | 0.150 |
Why?
|
| Gadolinium | 5 | 2023 | 111 | 0.150 |
Why?
|
| Image Enhancement | 3 | 2020 | 168 | 0.150 |
Why?
|
| Kynurenine | 1 | 2019 | 24 | 0.150 |
Why?
|
| Apyrase | 1 | 2019 | 21 | 0.150 |
Why?
|
| Cerebrospinal Fluid Shunts | 3 | 2001 | 99 | 0.150 |
Why?
|
| Proteolysis | 1 | 2020 | 193 | 0.150 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2023 | 266 | 0.150 |
Why?
|
| Cell Adhesion Molecules, Neuronal | 1 | 2019 | 82 | 0.150 |
Why?
|
| Drug Resistance | 3 | 2011 | 247 | 0.150 |
Why?
|
| Skull Neoplasms | 1 | 1999 | 16 | 0.150 |
Why?
|
| Steroids | 1 | 2020 | 170 | 0.150 |
Why?
|
| Rotarod Performance Test | 1 | 2018 | 14 | 0.150 |
Why?
|
| Protease Inhibitors | 1 | 2019 | 95 | 0.150 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2022 | 582 | 0.150 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2018 | 2 | 0.150 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2018 | 12 | 0.150 |
Why?
|
| Optic Nerve | 1 | 2020 | 114 | 0.150 |
Why?
|
| Caloric Restriction | 1 | 2019 | 107 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-maf | 1 | 2018 | 11 | 0.140 |
Why?
|
| Dura Mater | 1 | 1999 | 29 | 0.140 |
Why?
|
| Head and Neck Neoplasms | 2 | 2019 | 633 | 0.140 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2018 | 13 | 0.140 |
Why?
|
| Myelin-Oligodendrocyte Glycoprotein | 2 | 2020 | 35 | 0.140 |
Why?
|
| Magnetoencephalography | 2 | 2025 | 41 | 0.140 |
Why?
|
| C-Reactive Protein | 1 | 2021 | 450 | 0.140 |
Why?
|
| Minocycline | 1 | 2018 | 43 | 0.140 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2021 | 219 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2021 | 307 | 0.140 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2018 | 33 | 0.140 |
Why?
|
| Skull Fractures | 1 | 1999 | 48 | 0.140 |
Why?
|
| PPAR gamma | 1 | 2018 | 87 | 0.140 |
Why?
|
| Temporal Lobe | 3 | 2016 | 109 | 0.140 |
Why?
|
| Plaque, Amyloid | 3 | 2025 | 68 | 0.140 |
Why?
|
| Pituitary-Adrenal System | 1 | 2018 | 32 | 0.140 |
Why?
|
| Proteome | 1 | 2020 | 289 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 3 | 2021 | 499 | 0.140 |
Why?
|
| Interleukin-17 | 3 | 2026 | 126 | 0.130 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2018 | 56 | 0.130 |
Why?
|
| Cell Differentiation | 5 | 2026 | 1917 | 0.130 |
Why?
|
| Radiopharmaceuticals | 1 | 2018 | 163 | 0.130 |
Why?
|
| Cytarabine | 1 | 2018 | 99 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2016 | 1211 | 0.130 |
Why?
|
| Medical Oncology | 1 | 1999 | 239 | 0.130 |
Why?
|
| Prognosis | 8 | 2025 | 4901 | 0.130 |
Why?
|
| Face | 1 | 2019 | 189 | 0.130 |
Why?
|
| Stroke | 1 | 2025 | 1054 | 0.130 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2015 | 356 | 0.130 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2018 | 528 | 0.130 |
Why?
|
| Comorbidity | 2 | 2020 | 1587 | 0.130 |
Why?
|
| Th1 Cells | 1 | 2017 | 156 | 0.130 |
Why?
|
| Nerve Net | 1 | 2020 | 264 | 0.130 |
Why?
|
| Mass Spectrometry | 2 | 2020 | 360 | 0.130 |
Why?
|
| Embryo, Mammalian | 2 | 2013 | 400 | 0.130 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2016 | 237 | 0.130 |
Why?
|
| Spinal Osteophytosis | 2 | 1993 | 4 | 0.130 |
Why?
|
| Anticonvulsants | 3 | 2011 | 359 | 0.120 |
Why?
|
| Genetic Association Studies | 1 | 2020 | 823 | 0.120 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2018 | 1311 | 0.120 |
Why?
|
| Virology | 1 | 2016 | 31 | 0.120 |
Why?
|
| Forkhead Transcription Factors | 2 | 2016 | 372 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2018 | 441 | 0.120 |
Why?
|
| Allergy and Immunology | 1 | 2016 | 29 | 0.120 |
Why?
|
| CD56 Antigen | 1 | 2016 | 26 | 0.120 |
Why?
|
| Cell Communication | 2 | 2016 | 186 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2018 | 296 | 0.120 |
Why?
|
| Nervous System Neoplasms | 1 | 2016 | 7 | 0.120 |
Why?
|
| Aging | 2 | 2021 | 1251 | 0.120 |
Why?
|
| Mutation | 4 | 2018 | 6129 | 0.120 |
Why?
|
| Therapy, Computer-Assisted | 1 | 1996 | 27 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2015 | 832 | 0.120 |
Why?
|
| Integrins | 1 | 1996 | 90 | 0.120 |
Why?
|
| Leukemia, Radiation-Induced | 1 | 2015 | 2 | 0.120 |
Why?
|
| Animals, Congenic | 1 | 2015 | 7 | 0.120 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2015 | 5 | 0.120 |
Why?
|
| Third Ventricle | 3 | 2015 | 32 | 0.120 |
Why?
|
| Ventriculostomy | 3 | 2015 | 46 | 0.120 |
Why?
|
| Hydrocephalus, Normal Pressure | 1 | 1995 | 6 | 0.120 |
Why?
|
| Transcription Factors | 2 | 2002 | 2437 | 0.120 |
Why?
|
| Models, Statistical | 2 | 2016 | 482 | 0.120 |
Why?
|
| Bereavement | 1 | 1995 | 20 | 0.120 |
Why?
|
| Grief | 1 | 1995 | 21 | 0.120 |
Why?
|
| Personality Inventory | 2 | 1995 | 175 | 0.110 |
Why?
|
| Pneumonia, Pneumococcal | 1 | 2016 | 88 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 3 | 2008 | 1454 | 0.110 |
Why?
|
| Amyloid beta-Peptides | 3 | 2025 | 235 | 0.110 |
Why?
|
| Membrane Glycoproteins | 1 | 2017 | 411 | 0.110 |
Why?
|
| Sodium-Hydrogen Exchangers | 1 | 2015 | 28 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 4 | 2025 | 453 | 0.110 |
Why?
|
| Parkinson Disease | 1 | 2022 | 722 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2015 | 122 | 0.110 |
Why?
|
| Artifacts | 1 | 2016 | 104 | 0.110 |
Why?
|
| Cerebellum | 3 | 2012 | 445 | 0.110 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 363 | 0.110 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 417 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.110 |
Why?
|
| Internship and Residency | 1 | 2025 | 1211 | 0.110 |
Why?
|
| Fetal Death | 1 | 1995 | 118 | 0.110 |
Why?
|
| Environment | 1 | 2015 | 148 | 0.110 |
Why?
|
| Cross-Sectional Studies | 6 | 2024 | 3805 | 0.110 |
Why?
|
| DNA Methylation | 1 | 2021 | 1094 | 0.110 |
Why?
|
| Galactosyltransferases | 1 | 2014 | 8 | 0.110 |
Why?
|
| Health Personnel | 1 | 2020 | 548 | 0.110 |
Why?
|
| Glycolipids | 1 | 2014 | 33 | 0.110 |
Why?
|
| Craniopharyngioma | 1 | 1994 | 34 | 0.110 |
Why?
|
| Neurology | 1 | 2016 | 115 | 0.110 |
Why?
|
| Hedgehog Proteins | 3 | 2005 | 200 | 0.110 |
Why?
|
| Abortion, Spontaneous | 1 | 1995 | 82 | 0.110 |
Why?
|
| Anti-Bacterial Agents | 3 | 2025 | 2546 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2000 | 1215 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1292 | 0.110 |
Why?
|
| Memory Disorders | 1 | 2016 | 204 | 0.110 |
Why?
|
| Propylene Glycols | 1 | 2014 | 18 | 0.110 |
Why?
|
| Sphingosine | 1 | 2014 | 21 | 0.110 |
Why?
|
| Surveys and Questionnaires | 4 | 2025 | 4015 | 0.110 |
Why?
|
| JC Virus | 1 | 2014 | 26 | 0.110 |
Why?
|
| Autoantigens | 1 | 2014 | 99 | 0.110 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2018 | 325 | 0.110 |
Why?
|
| Tomography, X-Ray Computed | 4 | 2023 | 2110 | 0.100 |
Why?
|
| Infant, Newborn | 6 | 2025 | 8525 | 0.100 |
Why?
|
| Receptors, Purinergic P2Y12 | 1 | 2013 | 5 | 0.100 |
Why?
|
| Clinical Trials as Topic | 4 | 2008 | 1126 | 0.100 |
Why?
|
| Chromatography, Ion Exchange | 1 | 2013 | 38 | 0.100 |
Why?
|
| Pituitary Neoplasms | 1 | 1994 | 80 | 0.100 |
Why?
|
| Sepsis | 1 | 2018 | 494 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2013 | 33 | 0.100 |
Why?
|
| Serologic Tests | 1 | 2014 | 125 | 0.100 |
Why?
|
| New York | 1 | 2013 | 69 | 0.100 |
Why?
|
| Killer Cells, Natural | 1 | 2016 | 341 | 0.100 |
Why?
|
| Contrast Media | 5 | 2016 | 492 | 0.100 |
Why?
|
| Optic Neuritis | 1 | 2014 | 36 | 0.100 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 135 | 0.100 |
Why?
|
| Sigmoid Diseases | 1 | 1993 | 7 | 0.100 |
Why?
|
| Ventriculoperitoneal Shunt | 2 | 2009 | 63 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2013 | 100 | 0.100 |
Why?
|
| Topotecan | 1 | 2013 | 49 | 0.100 |
Why?
|
| Nerve Compression Syndromes | 1 | 1993 | 13 | 0.100 |
Why?
|
| Laminectomy | 1 | 1993 | 25 | 0.100 |
Why?
|
| Spinal Nerve Roots | 1 | 1993 | 17 | 0.100 |
Why?
|
| RNA, Untranslated | 1 | 2014 | 109 | 0.100 |
Why?
|
| Epidemiologic Research Design | 1 | 2013 | 6 | 0.100 |
Why?
|
| Lung | 1 | 2021 | 1568 | 0.100 |
Why?
|
| Diverticulum | 1 | 1993 | 23 | 0.100 |
Why?
|
| Spinal Cord Compression | 1 | 1993 | 30 | 0.100 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 1993 | 68 | 0.100 |
Why?
|
| Epitopes | 1 | 2014 | 322 | 0.100 |
Why?
|
| Blood Proteins | 2 | 2024 | 139 | 0.100 |
Why?
|
| Intestinal Perforation | 1 | 1993 | 50 | 0.100 |
Why?
|
| Azathioprine | 1 | 2013 | 37 | 0.100 |
Why?
|
| Memory | 1 | 2016 | 354 | 0.100 |
Why?
|
| Facial Paralysis | 1 | 1993 | 36 | 0.100 |
Why?
|
| Cerebral Ventricles | 2 | 2012 | 83 | 0.100 |
Why?
|
| Medical Records | 1 | 2013 | 177 | 0.100 |
Why?
|
| Intracranial Aneurysm | 1 | 1993 | 89 | 0.100 |
Why?
|
| Functional Laterality | 2 | 2011 | 178 | 0.100 |
Why?
|
| Panama | 2 | 2025 | 16 | 0.100 |
Why?
|
| Aspartic Acid | 1 | 2013 | 78 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2015 | 316 | 0.090 |
Why?
|
| Mycophenolic Acid | 1 | 2013 | 62 | 0.090 |
Why?
|
| Methotrexate | 2 | 2013 | 336 | 0.090 |
Why?
|
| Neurilemmoma | 1 | 1993 | 41 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2013 | 185 | 0.090 |
Why?
|
| Guidelines as Topic | 1 | 2013 | 200 | 0.090 |
Why?
|
| Colorectal Neoplasms | 1 | 2018 | 624 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1995 | 604 | 0.090 |
Why?
|
| Monitoring, Intraoperative | 2 | 2004 | 129 | 0.090 |
Why?
|
| Caudate Nucleus | 1 | 2012 | 35 | 0.090 |
Why?
|
| Antigens, Surface | 4 | 2009 | 112 | 0.090 |
Why?
|
| Administration, Oral | 4 | 2025 | 695 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2013 | 938 | 0.090 |
Why?
|
| Organ Size | 3 | 2017 | 423 | 0.090 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2018 | 575 | 0.090 |
Why?
|
| Verbal Behavior | 1 | 2011 | 44 | 0.090 |
Why?
|
| Blood Platelet Disorders | 1 | 2011 | 14 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2022 | 298 | 0.090 |
Why?
|
| RNA, Messenger | 5 | 2017 | 2553 | 0.090 |
Why?
|
| Blood Coagulation Tests | 1 | 2011 | 66 | 0.090 |
Why?
|
| Choroid Plexus Neoplasms | 1 | 2011 | 11 | 0.080 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1993 | 331 | 0.080 |
Why?
|
| Brain Diseases | 1 | 2014 | 302 | 0.080 |
Why?
|
| Visual Acuity | 1 | 2014 | 529 | 0.080 |
Why?
|
| Platelet Aggregation | 1 | 2011 | 103 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2011 | 95 | 0.080 |
Why?
|
| Suction | 1 | 2011 | 50 | 0.080 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2016 | 494 | 0.080 |
Why?
|
| Haplotypes | 2 | 2022 | 522 | 0.080 |
Why?
|
| Disease-Free Survival | 5 | 2014 | 900 | 0.080 |
Why?
|
| Combined Modality Therapy | 5 | 2010 | 1233 | 0.080 |
Why?
|
| Statistics as Topic | 1 | 2011 | 239 | 0.080 |
Why?
|
| Body Mass Index | 2 | 2014 | 1682 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2013 | 1014 | 0.080 |
Why?
|
| Memory, Short-Term | 1 | 2011 | 139 | 0.080 |
Why?
|
| Cerebrospinal Fluid | 2 | 2002 | 100 | 0.080 |
Why?
|
| Blood Coagulation Disorders | 1 | 2011 | 104 | 0.080 |
Why?
|
| Pregnancy | 4 | 2025 | 7423 | 0.080 |
Why?
|
| Internet | 1 | 2013 | 418 | 0.080 |
Why?
|
| Anatomy, Cross-Sectional | 1 | 2009 | 18 | 0.080 |
Why?
|
| Lymphocyte Activation | 3 | 2009 | 628 | 0.080 |
Why?
|
| Preoperative Care | 2 | 2009 | 356 | 0.080 |
Why?
|
| Cell Migration Inhibition | 1 | 2009 | 8 | 0.080 |
Why?
|
| Paresis | 1 | 2009 | 33 | 0.080 |
Why?
|
| Health Status | 2 | 2009 | 367 | 0.080 |
Why?
|
| Risk Factors | 8 | 2021 | 10981 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2010 | 225 | 0.080 |
Why?
|
| Bacteria | 2 | 2024 | 536 | 0.070 |
Why?
|
| Cranial Nerve Diseases | 1 | 2009 | 28 | 0.070 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2015 | 754 | 0.070 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2013 | 976 | 0.070 |
Why?
|
| Biopsy | 4 | 2015 | 1239 | 0.070 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 6773 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2014 | 1077 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2026 | 640 | 0.070 |
Why?
|
| Health Surveys | 1 | 2009 | 255 | 0.070 |
Why?
|
| Arnold-Chiari Malformation | 1 | 2009 | 56 | 0.070 |
Why?
|
| Cognition | 2 | 2014 | 814 | 0.070 |
Why?
|
| Intelligence | 2 | 2016 | 103 | 0.070 |
Why?
|
| Medulla Oblongata | 1 | 2008 | 23 | 0.070 |
Why?
|
| Disease Susceptibility | 2 | 2021 | 280 | 0.070 |
Why?
|
| Wakefulness | 1 | 2009 | 103 | 0.070 |
Why?
|
| Testosterone | 1 | 2014 | 590 | 0.070 |
Why?
|
| Carcinoma | 1 | 2011 | 284 | 0.070 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2011 | 240 | 0.070 |
Why?
|
| HLA-DRB1 Chains | 2 | 2022 | 46 | 0.070 |
Why?
|
| Age Factors | 3 | 2015 | 2835 | 0.070 |
Why?
|
| Syndrome | 2 | 2022 | 1160 | 0.070 |
Why?
|
| Lactosylceramides | 2 | 2020 | 7 | 0.070 |
Why?
|
| Software | 1 | 2013 | 737 | 0.070 |
Why?
|
| Antibodies, Viral | 1 | 2014 | 1166 | 0.070 |
Why?
|
| Statistics, Nonparametric | 3 | 2017 | 427 | 0.070 |
Why?
|
| Lumbosacral Region | 1 | 2007 | 22 | 0.070 |
Why?
|
| Equipment Failure | 3 | 2010 | 130 | 0.070 |
Why?
|
| Gadolinium DTPA | 2 | 2007 | 49 | 0.070 |
Why?
|
| Emotions | 2 | 2024 | 350 | 0.060 |
Why?
|
| Autistic Disorder | 1 | 2011 | 396 | 0.060 |
Why?
|
| Hospitalization | 1 | 2016 | 1927 | 0.060 |
Why?
|
| Paraplegia | 1 | 2007 | 87 | 0.060 |
Why?
|
| Social Support | 1 | 2009 | 364 | 0.060 |
Why?
|
| Nerve Regeneration | 1 | 2007 | 68 | 0.060 |
Why?
|
| Neoplasm, Residual | 2 | 1999 | 132 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2008 | 180 | 0.060 |
Why?
|
| Proteins | 2 | 2003 | 1006 | 0.060 |
Why?
|
| Incidence | 3 | 2024 | 3346 | 0.060 |
Why?
|
| Drug Therapy, Combination | 3 | 2005 | 1163 | 0.060 |
Why?
|
| DNA Glycosylases | 1 | 2026 | 26 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2022 | 738 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2009 | 457 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2007 | 209 | 0.060 |
Why?
|
| Zinc Finger Protein GLI1 | 2 | 2002 | 33 | 0.060 |
Why?
|
| Microarray Analysis | 2 | 2018 | 224 | 0.060 |
Why?
|
| Iron | 1 | 2009 | 305 | 0.060 |
Why?
|
| Algorithms | 3 | 2023 | 1680 | 0.060 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 379 | 0.060 |
Why?
|
| Neural Pathways | 1 | 2007 | 280 | 0.060 |
Why?
|
| Research Support as Topic | 1 | 2025 | 62 | 0.060 |
Why?
|
| Immunoglobulin G | 3 | 2020 | 790 | 0.060 |
Why?
|
| Smad2 Protein | 1 | 2025 | 54 | 0.060 |
Why?
|
| Oxidation-Reduction | 1 | 2026 | 435 | 0.060 |
Why?
|
| Amino Acid Sequence | 2 | 2021 | 2397 | 0.060 |
Why?
|
| Aldehyde Dehydrogenase | 1 | 1985 | 41 | 0.060 |
Why?
|
| Interleukin-23 | 1 | 2024 | 16 | 0.050 |
Why?
|
| Mitochondria, Liver | 1 | 1985 | 37 | 0.050 |
Why?
|
| Observer Variation | 1 | 2025 | 311 | 0.050 |
Why?
|
| Neoplasms | 1 | 2000 | 2946 | 0.050 |
Why?
|
| Evoked Potentials, Auditory | 1 | 2024 | 46 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2018 | 60 | 0.050 |
Why?
|
| Acoustic Stimulation | 1 | 2024 | 92 | 0.050 |
Why?
|
| Belgium | 2 | 2014 | 43 | 0.050 |
Why?
|
| Pinealoma | 1 | 2024 | 20 | 0.050 |
Why?
|
| Gene Expression | 2 | 2021 | 1488 | 0.050 |
Why?
|
| Administration, Inhalation | 1 | 2025 | 192 | 0.050 |
Why?
|
| Infusions, Intravenous | 3 | 2012 | 544 | 0.050 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 148 | 0.050 |
Why?
|
| Acute Disease | 1 | 2007 | 1150 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2017 | 417 | 0.050 |
Why?
|
| NF-kappa B | 1 | 2026 | 440 | 0.050 |
Why?
|
| Smoking | 1 | 2009 | 930 | 0.050 |
Why?
|
| Equipment Design | 2 | 2016 | 541 | 0.050 |
Why?
|
| Mice, Inbred DBA | 2 | 2019 | 43 | 0.050 |
Why?
|
| Intermediate Filaments | 1 | 2023 | 10 | 0.050 |
Why?
|
| Peptide Fragments | 2 | 2020 | 685 | 0.050 |
Why?
|
| Job Satisfaction | 1 | 2024 | 100 | 0.050 |
Why?
|
| Neuronavigation | 2 | 2015 | 10 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2021 | 1840 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2015 | 380 | 0.050 |
Why?
|
| Anti-Glomerular Basement Membrane Disease | 1 | 2003 | 8 | 0.050 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2003 | 47 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2026 | 377 | 0.050 |
Why?
|
| Syncope | 1 | 2023 | 53 | 0.050 |
Why?
|
| Parents | 1 | 2011 | 1109 | 0.050 |
Why?
|
| Antigens | 2 | 2008 | 104 | 0.050 |
Why?
|
| Corpus Callosum | 1 | 2023 | 109 | 0.050 |
Why?
|
| Alleles | 2 | 2022 | 1672 | 0.050 |
Why?
|
| Reactive Oxygen Species | 1 | 2026 | 510 | 0.050 |
Why?
|
| Public Opinion | 1 | 2023 | 63 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1983 | 61 | 0.050 |
Why?
|
| Dacarbazine | 1 | 2003 | 94 | 0.050 |
Why?
|
| Protein Kinases | 1 | 2004 | 317 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2023 | 125 | 0.050 |
Why?
|
| Receptors, GABA | 1 | 2022 | 16 | 0.050 |
Why?
|
| Administration, Cutaneous | 2 | 2012 | 65 | 0.050 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2003 | 98 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 40 | 0.050 |
Why?
|
| Tumor Cells, Cultured | 2 | 2001 | 968 | 0.050 |
Why?
|
| Retroviridae | 1 | 2002 | 182 | 0.050 |
Why?
|
| Immunity, Cellular | 1 | 2003 | 191 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 358 | 0.050 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2023 | 176 | 0.050 |
Why?
|
| Plasma Exchange | 1 | 1983 | 86 | 0.040 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 2001 | 6 | 0.040 |
Why?
|
| Demography | 2 | 2013 | 238 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2024 | 3408 | 0.040 |
Why?
|
| Registries | 2 | 2021 | 1603 | 0.040 |
Why?
|
| Linkage Disequilibrium | 1 | 2022 | 317 | 0.040 |
Why?
|
| Knowledge | 1 | 2022 | 48 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2022 | 100 | 0.040 |
Why?
|
| Cerebral Aqueduct | 1 | 2001 | 10 | 0.040 |
Why?
|
| Stakeholder Participation | 1 | 2022 | 35 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 2 | 2019 | 231 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2025 | 1569 | 0.040 |
Why?
|
| Logistic Models | 2 | 2021 | 1807 | 0.040 |
Why?
|
| Viral Proteins | 1 | 2003 | 339 | 0.040 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2021 | 55 | 0.040 |
Why?
|
| Canada | 1 | 2022 | 321 | 0.040 |
Why?
|
| Complementarity Determining Regions | 1 | 2021 | 26 | 0.040 |
Why?
|
| Discoidin Domain Receptors | 1 | 2000 | 3 | 0.040 |
Why?
|
| alpha-Synuclein | 1 | 2022 | 141 | 0.040 |
Why?
|
| Cerebral Hemorrhage | 1 | 2002 | 161 | 0.040 |
Why?
|
| Phantoms, Imaging | 1 | 2001 | 144 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2023 | 378 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2026 | 1949 | 0.040 |
Why?
|
| Risk | 1 | 2022 | 731 | 0.040 |
Why?
|
| Models, Biological | 1 | 2006 | 1387 | 0.040 |
Why?
|
| British Columbia | 1 | 2020 | 10 | 0.040 |
Why?
|
| Hyponatremia | 1 | 2001 | 72 | 0.040 |
Why?
|
| Urinary Bladder | 1 | 2022 | 219 | 0.040 |
Why?
|
| Protein Binding | 1 | 2024 | 1657 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 1999 | 1893 | 0.040 |
Why?
|
| Hydroxybutyrates | 1 | 2020 | 31 | 0.040 |
Why?
|
| Gestational Age | 1 | 2024 | 1223 | 0.040 |
Why?
|
| Boston | 1 | 2020 | 118 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 1333 | 0.040 |
Why?
|
| Developmental Disabilities | 1 | 2005 | 773 | 0.040 |
Why?
|
| Research | 1 | 2022 | 264 | 0.040 |
Why?
|
| Discoidin Domain Receptor 1 | 1 | 2000 | 8 | 0.040 |
Why?
|
| Immunomodulation | 1 | 2020 | 80 | 0.040 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2000 | 23 | 0.040 |
Why?
|
| Focal Adhesion Protein-Tyrosine Kinases | 1 | 2000 | 25 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2000 | 358 | 0.040 |
Why?
|
| Selection Bias | 1 | 1999 | 17 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2021 | 2846 | 0.040 |
Why?
|
| Biological Assay | 1 | 2020 | 106 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 209 | 0.040 |
Why?
|
| Nitriles | 1 | 2020 | 161 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2025 | 752 | 0.040 |
Why?
|
| Cell Movement | 1 | 2003 | 863 | 0.040 |
Why?
|
| Goals | 1 | 2020 | 126 | 0.040 |
Why?
|
| Pharmacogenomic Testing | 1 | 2019 | 47 | 0.040 |
Why?
|
| Sirolimus | 2 | 2013 | 229 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2022 | 227 | 0.040 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2019 | 53 | 0.040 |
Why?
|
| Birth Injuries | 1 | 1999 | 20 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2018 | 2015 | 0.040 |
Why?
|
| Withholding Treatment | 1 | 2019 | 75 | 0.040 |
Why?
|
| Aminosalicylic Acid | 1 | 2018 | 2 | 0.040 |
Why?
|
| Maxilla | 1 | 2019 | 41 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 529 | 0.040 |
Why?
|
| Dextran Sulfate | 1 | 2018 | 48 | 0.040 |
Why?
|
| Chromatin | 1 | 2022 | 502 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 76 | 0.040 |
Why?
|
| Repressor Proteins | 1 | 2003 | 773 | 0.040 |
Why?
|
| Medical History Taking | 1 | 1999 | 109 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2002 | 1501 | 0.040 |
Why?
|
| Kinetics | 2 | 2014 | 1086 | 0.040 |
Why?
|
| Interferons | 1 | 2019 | 136 | 0.040 |
Why?
|
| Cell Proliferation | 2 | 2016 | 2467 | 0.040 |
Why?
|
| Dexamethasone | 1 | 2020 | 250 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2021 | 814 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2018 | 42 | 0.030 |
Why?
|
| Head | 1 | 2019 | 111 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2018 | 38 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2018 | 50 | 0.030 |
Why?
|
| International Cooperation | 1 | 2018 | 156 | 0.030 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 360 | 0.030 |
Why?
|
| Data Interpretation, Statistical | 2 | 2011 | 227 | 0.030 |
Why?
|
| Salvage Therapy | 2 | 2010 | 174 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2016 | 1610 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2017 | 25 | 0.030 |
Why?
|
| Growth Disorders | 1 | 1999 | 183 | 0.030 |
Why?
|
| Arrestin | 1 | 1997 | 3 | 0.030 |
Why?
|
| Intracranial Hypertension | 1 | 1999 | 138 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2010 | 1608 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 1999 | 142 | 0.030 |
Why?
|
| Cervical Cord | 1 | 2017 | 9 | 0.030 |
Why?
|
| Remission Induction | 1 | 2018 | 299 | 0.030 |
Why?
|
| Disease Management | 1 | 2021 | 559 | 0.030 |
Why?
|
| Tomography Scanners, X-Ray Computed | 1 | 2017 | 20 | 0.030 |
Why?
|
| Uveitis | 1 | 1997 | 33 | 0.030 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2017 | 23 | 0.030 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 1996 | 15 | 0.030 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2017 | 116 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 284 | 0.030 |
Why?
|
| Ki-67 Antigen | 1 | 2017 | 105 | 0.030 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2016 | 23 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2017 | 154 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 1 | 1 | 2016 | 2 | 0.030 |
Why?
|
| Natural Cytotoxicity Triggering Receptor 2 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Ganglioglioma | 1 | 1996 | 21 | 0.030 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily K | 1 | 2016 | 13 | 0.030 |
Why?
|
| Injections, Subcutaneous | 1 | 2016 | 134 | 0.030 |
Why?
|
| Pheochromocytoma | 1 | 1996 | 32 | 0.030 |
Why?
|
| History, 19th Century | 1 | 2016 | 111 | 0.030 |
Why?
|
| Granzymes | 1 | 2016 | 45 | 0.030 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 1996 | 44 | 0.030 |
Why?
|
| Visual Cortex | 1 | 2018 | 130 | 0.030 |
Why?
|
| Risk Assessment | 2 | 2015 | 3692 | 0.030 |
Why?
|
| Thiazoles | 1 | 2016 | 109 | 0.030 |
Why?
|
| Equipment Failure Analysis | 1 | 2016 | 82 | 0.030 |
Why?
|
| Intraoperative Period | 1 | 2015 | 65 | 0.030 |
Why?
|
| Cerebrospinal Fluid Pressure | 1 | 1995 | 18 | 0.030 |
Why?
|
| Sclerosis | 2 | 2008 | 31 | 0.030 |
Why?
|
| In Situ Hybridization | 2 | 2008 | 440 | 0.030 |
Why?
|
| Adjustment Disorders | 1 | 1995 | 5 | 0.030 |
Why?
|
| Genes, BRCA2 | 1 | 2015 | 48 | 0.030 |
Why?
|
| Spinal Dysraphism | 1 | 2019 | 279 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2019 | 518 | 0.030 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1996 | 67 | 0.030 |
Why?
|
| Linear Models | 1 | 2017 | 689 | 0.030 |
Why?
|
| Platelet Activating Factor | 1 | 2015 | 22 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2018 | 345 | 0.030 |
Why?
|
| Radiography | 2 | 2014 | 750 | 0.030 |
Why?
|
| Genes, BRCA1 | 1 | 2015 | 59 | 0.030 |
Why?
|
| Hospitals | 1 | 2018 | 436 | 0.030 |
Why?
|
| Platelet Factor 4 | 1 | 2015 | 22 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2016 | 1625 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 256 | 0.030 |
Why?
|
| Texas | 1 | 2024 | 3614 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2015 | 121 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2008 | 310 | 0.030 |
Why?
|
| Neurologic Examination | 1 | 1995 | 185 | 0.030 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 778 | 0.030 |
Why?
|
| Europe | 1 | 2016 | 366 | 0.030 |
Why?
|
| Pituitary Irradiation | 1 | 1994 | 1 | 0.030 |
Why?
|
| Hypophysectomy | 1 | 1994 | 21 | 0.030 |
Why?
|
| Spinal Cord Diseases | 1 | 2015 | 33 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2018 | 451 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 360 | 0.030 |
Why?
|
| Dandy-Walker Syndrome | 1 | 1995 | 13 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2015 | 232 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2018 | 450 | 0.030 |
Why?
|
| Thoracic Vertebrae | 1 | 2015 | 76 | 0.030 |
Why?
|
| CX3C Chemokine Receptor 1 | 1 | 2014 | 13 | 0.030 |
Why?
|
| Gait | 1 | 1995 | 132 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 1994 | 75 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2015 | 392 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2014 | 23 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2014 | 47 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1994 | 157 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 812 | 0.030 |
Why?
|
| Serotonin | 1 | 2015 | 211 | 0.030 |
Why?
|
| Obesity | 1 | 2026 | 2383 | 0.030 |
Why?
|
| Cell Shape | 1 | 2014 | 68 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2019 | 696 | 0.030 |
Why?
|
| Renin | 1 | 1994 | 75 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 112 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2011 | 1315 | 0.030 |
Why?
|
| Poland | 1 | 2014 | 56 | 0.030 |
Why?
|
| RNA Isoforms | 1 | 2013 | 3 | 0.030 |
Why?
|
| Molecular Sequence Data | 2 | 1996 | 3487 | 0.030 |
Why?
|
| Ranvier's Nodes | 1 | 2014 | 73 | 0.030 |
Why?
|
| Phorbol Esters | 1 | 2013 | 21 | 0.030 |
Why?
|
| Retina | 1 | 1997 | 452 | 0.030 |
Why?
|
| Occult Blood | 1 | 1993 | 32 | 0.030 |
Why?
|
| Chemokine CXCL10 | 1 | 2013 | 52 | 0.030 |
Why?
|
| Spinal Stenosis | 1 | 1993 | 9 | 0.030 |
Why?
|
| Abdomen, Acute | 1 | 1993 | 13 | 0.020 |
Why?
|
| Nerve Degeneration | 1 | 2014 | 134 | 0.020 |
Why?
|
| Inositol | 1 | 2013 | 14 | 0.020 |
Why?
|
| Survivors | 1 | 2015 | 345 | 0.020 |
Why?
|
| Cerebral Angiography | 1 | 1993 | 109 | 0.020 |
Why?
|
| Germ-Line Mutation | 1 | 2015 | 372 | 0.020 |
Why?
|
| Genomics | 1 | 2021 | 1619 | 0.020 |
Why?
|
| Duodenal Diseases | 1 | 1993 | 28 | 0.020 |
Why?
|
| Creatine | 1 | 2013 | 38 | 0.020 |
Why?
|
| Sample Size | 1 | 2013 | 85 | 0.020 |
Why?
|
| Peritonitis | 1 | 1993 | 74 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 661 | 0.020 |
Why?
|
| Methylprednisolone | 1 | 1993 | 95 | 0.020 |
Why?
|
| Choline | 1 | 2013 | 51 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2016 | 677 | 0.020 |
Why?
|
| Diplopia | 1 | 1993 | 43 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1994 | 629 | 0.020 |
Why?
|
| ROC Curve | 1 | 2014 | 610 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 1154 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2012 | 117 | 0.020 |
Why?
|
| Family | 1 | 2015 | 579 | 0.020 |
Why?
|
| Glutamine | 1 | 2013 | 204 | 0.020 |
Why?
|
| Vitamin D | 1 | 2014 | 198 | 0.020 |
Why?
|
| Treatment Failure | 1 | 1993 | 351 | 0.020 |
Why?
|
| Videotape Recording | 2 | 2002 | 54 | 0.020 |
Why?
|
| Rats | 1 | 2018 | 3374 | 0.020 |
Why?
|
| Molecular Sequence Annotation | 1 | 2012 | 150 | 0.020 |
Why?
|
| Parietal Lobe | 2 | 2002 | 47 | 0.020 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2020 | 1151 | 0.020 |
Why?
|
| Gene Regulatory Networks | 1 | 2014 | 384 | 0.020 |
Why?
|
| Psychometrics | 1 | 1995 | 668 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2019 | 3702 | 0.020 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 1991 | 6 | 0.020 |
Why?
|
| Preoperative Period | 1 | 2011 | 91 | 0.020 |
Why?
|
| Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1991 | 15 | 0.020 |
Why?
|
| Walking | 1 | 2013 | 214 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2011 | 114 | 0.020 |
Why?
|
| Arginine | 1 | 2013 | 336 | 0.020 |
Why?
|
| Blotting, Western | 2 | 2003 | 1014 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 810 | 0.020 |
Why?
|
| Surgical Wound Infection | 1 | 1993 | 265 | 0.020 |
Why?
|
| HLA-DR Antigens | 1 | 2010 | 64 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1840 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 1993 | 190 | 0.020 |
Why?
|
| Depression | 1 | 2019 | 1316 | 0.020 |
Why?
|
| Bevacizumab | 1 | 2010 | 60 | 0.020 |
Why?
|
| Camptothecin | 1 | 2010 | 77 | 0.020 |
Why?
|
| Drug Tolerance | 1 | 1969 | 37 | 0.020 |
Why?
|
| Jews | 1 | 1969 | 34 | 0.020 |
Why?
|
| Brain Infarction | 1 | 2009 | 28 | 0.020 |
Why?
|
| Patient Selection | 1 | 2013 | 719 | 0.020 |
Why?
|
| Cerebral Palsy | 1 | 2010 | 86 | 0.020 |
Why?
|
| Stress, Psychological | 1 | 1994 | 544 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2011 | 323 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2014 | 1089 | 0.020 |
Why?
|
| Subacute Sclerosing Panencephalitis | 1 | 1988 | 3 | 0.020 |
Why?
|
| DNA Probes | 2 | 2003 | 118 | 0.020 |
Why?
|
| Debridement | 1 | 2008 | 87 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2009 | 319 | 0.020 |
Why?
|
| Meningoencephalitis | 1 | 1988 | 19 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 1988 | 24 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 302 | 0.020 |
Why?
|
| Neoadjuvant Therapy | 1 | 2010 | 394 | 0.020 |
Why?
|
| Rett Syndrome | 1 | 2010 | 229 | 0.020 |
Why?
|
| Age Distribution | 1 | 2009 | 424 | 0.020 |
Why?
|
| Giant Cells | 1 | 2008 | 33 | 0.020 |
Why?
|
| Proteoglycans | 1 | 2008 | 77 | 0.020 |
Why?
|
| Vimentin | 1 | 2008 | 59 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 561 | 0.020 |
Why?
|
| Electrodes | 1 | 2007 | 82 | 0.020 |
Why?
|
| Time | 1 | 2007 | 93 | 0.020 |
Why?
|
| Cortical Synchronization | 1 | 2007 | 10 | 0.020 |
Why?
|
| Gene Dosage | 1 | 2008 | 439 | 0.020 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2009 | 463 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1985 | 37 | 0.010 |
Why?
|
| Prevalence | 1 | 1993 | 2683 | 0.010 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1 | 1985 | 5 | 0.010 |
Why?
|
| Hypertension | 1 | 1994 | 1356 | 0.010 |
Why?
|
| Infusion Pumps | 1 | 2005 | 31 | 0.010 |
Why?
|
| Child Behavior Disorders | 1 | 2005 | 71 | 0.010 |
Why?
|
| Diethyl Pyrocarbonate | 1 | 1985 | 1 | 0.010 |
Why?
|
| Brain Injuries | 1 | 2010 | 702 | 0.010 |
Why?
|
| Mesna | 1 | 2004 | 6 | 0.010 |
Why?
|
| Methicillin Resistance | 1 | 2005 | 116 | 0.010 |
Why?
|
| Microdissection | 1 | 2004 | 13 | 0.010 |
Why?
|
| Ribosomal Protein S6 | 1 | 2004 | 14 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 18 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2008 | 747 | 0.010 |
Why?
|
| Histidine | 1 | 1985 | 69 | 0.010 |
Why?
|
| Meningitis | 1 | 2005 | 98 | 0.010 |
Why?
|
| Leucovorin | 1 | 2004 | 53 | 0.010 |
Why?
|
| Disulfiram | 1 | 1985 | 33 | 0.010 |
Why?
|
| Horses | 1 | 1985 | 93 | 0.010 |
Why?
|
| Eukaryotic Initiation Factors | 1 | 2004 | 36 | 0.010 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2004 | 40 | 0.010 |
Why?
|
| Etoposide | 1 | 2004 | 109 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 212 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 2004 | 261 | 0.010 |
Why?
|
| Cysteine | 1 | 1985 | 137 | 0.010 |
Why?
|
| Vincristine | 1 | 2004 | 189 | 0.010 |
Why?
|
| Mice, Inbred AKR | 1 | 2003 | 15 | 0.010 |
Why?
|
| Collagen Type IV | 1 | 2003 | 20 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2015 | 2617 | 0.010 |
Why?
|
| Research Design | 1 | 1987 | 716 | 0.010 |
Why?
|
| Cisplatin | 1 | 2004 | 271 | 0.010 |
Why?
|
| Kidney Glomerulus | 1 | 2003 | 80 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1983 | 238 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 431 | 0.010 |
Why?
|
| Species Specificity | 1 | 2003 | 486 | 0.010 |
Why?
|
| Tectum Mesencephali | 1 | 2001 | 3 | 0.010 |
Why?
|
| Binding Sites | 1 | 1985 | 1143 | 0.010 |
Why?
|
| Blood-Brain Barrier | 1 | 2003 | 154 | 0.010 |
Why?
|
| Random Allocation | 1 | 1983 | 416 | 0.010 |
Why?
|
| Veratrum Alkaloids | 1 | 2001 | 12 | 0.010 |
Why?
|
| Point Mutation | 1 | 2003 | 332 | 0.010 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2001 | 43 | 0.010 |
Why?
|
| Vasopressins | 1 | 2001 | 42 | 0.010 |
Why?
|
| Language Disorders | 1 | 2001 | 22 | 0.010 |
Why?
|
| Aldosterone | 1 | 2001 | 58 | 0.010 |
Why?
|
| Electrolytes | 1 | 2001 | 59 | 0.010 |
Why?
|
| Sodium Chloride | 1 | 2001 | 90 | 0.010 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2001 | 100 | 0.010 |
Why?
|
| Radiotherapy | 1 | 2001 | 120 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2001 | 227 | 0.010 |
Why?
|
| Sodium | 1 | 2001 | 280 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2005 | 562 | 0.010 |
Why?
|
| Cell Division | 1 | 2001 | 713 | 0.010 |
Why?
|
| DNA | 1 | 1985 | 1411 | 0.010 |
Why?
|
| Resuscitation | 1 | 2001 | 276 | 0.010 |
Why?
|
| Cell Line | 1 | 2003 | 2568 | 0.010 |
Why?
|
| Life Tables | 1 | 1997 | 26 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1997 | 101 | 0.010 |
Why?
|
| Infant, Premature | 1 | 2002 | 851 | 0.010 |
Why?
|
| Safety | 1 | 1997 | 213 | 0.010 |
Why?
|
| Cattle | 1 | 1997 | 501 | 0.010 |
Why?
|
| Cranial Nerve Injuries | 1 | 1995 | 5 | 0.010 |
Why?
|
| Anorexia Nervosa | 1 | 1974 | 31 | 0.010 |
Why?
|
| Foreign-Body Migration | 1 | 1995 | 59 | 0.010 |
Why?
|
| Luteinizing Hormone | 1 | 1974 | 129 | 0.010 |
Why?
|
| Defense Mechanisms | 1 | 1994 | 13 | 0.010 |
Why?
|
| Cysts | 1 | 1995 | 89 | 0.010 |
Why?
|
| Anger | 1 | 1994 | 31 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1991 | 202 | 0.010 |
Why?
|
| Aminopyrine | 1 | 1969 | 7 | 0.000 |
Why?
|
| Chloramphenicol | 1 | 1969 | 25 | 0.000 |
Why?
|
| Israel | 1 | 1969 | 48 | 0.000 |
Why?
|
| Anemia, Aplastic | 1 | 1969 | 61 | 0.000 |
Why?
|
| Anxiety | 1 | 1994 | 1001 | 0.000 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1987 | 70 | 0.000 |
Why?
|
| Base Sequence | 1 | 1991 | 2753 | 0.000 |
Why?
|
| HIV Infections | 1 | 1996 | 2011 | 0.000 |
Why?
|
| Fluorescence | 1 | 1980 | 94 | 0.000 |
Why?
|
| Leukocyte Count | 1 | 1980 | 249 | 0.000 |
Why?
|
| Radioimmunoassay | 1 | 1974 | 83 | 0.000 |
Why?
|
| Amenorrhea | 1 | 1974 | 19 | 0.000 |
Why?
|
| Sleep Stages | 1 | 1974 | 31 | 0.000 |
Why?
|
| Remission, Spontaneous | 1 | 1974 | 62 | 0.000 |
Why?
|
| Menarche | 1 | 1974 | 33 | 0.000 |
Why?
|
| Puberty | 1 | 1974 | 93 | 0.000 |
Why?
|
| Body Weight | 1 | 1974 | 986 | 0.000 |
Why?
|